MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial
(2013) In British Journal of Cancer 109(5). p.1243-1251- Abstract
- Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly... (More)
- Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly related to a longer progression-free survival. The independent prognostic value of miRNA-126 was confirmed using a Cox regression analysis (hazard ratio = 0.49, 95% confidence interval = 0.29-0.84, P = 0.009). Although not significant, a relationship between EGFL7 expression and response rates is suggested, with EGFL7 expression at the invasive front being lower in responding patients than in the non-responders (P = 0.063). Conclusion: The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA-126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4103141
- author
- Hansen, T. F. ; Christensen, R. Dp ; Andersen, R. F. ; Sorensen, F. B. ; Johnsson, Anders LU and Jakobsen, A.
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- angiogenesis, chemotherapy, colorectal neoplasms, epidermal growth, factor-like domain 7, microRNA, predictive biomarkers
- in
- British Journal of Cancer
- volume
- 109
- issue
- 5
- pages
- 1243 - 1251
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000324168500021
- scopus:84883742865
- pmid:23922111
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2013.448
- language
- English
- LU publication?
- yes
- id
- ef81c82e-56ed-4cae-b71a-3d20298cf43c (old id 4103141)
- date added to LUP
- 2016-04-01 09:49:08
- date last changed
- 2022-04-27 07:50:29
@article{ef81c82e-56ed-4cae-b71a-3d20298cf43c, abstract = {{Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal cancer (mCRC). Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126) A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was visualised and quantified using immunohistochemistry. Results: High tumour expression of miRNA-126 was significantly related to a longer progression-free survival. The independent prognostic value of miRNA-126 was confirmed using a Cox regression analysis (hazard ratio = 0.49, 95% confidence interval = 0.29-0.84, P = 0.009). Although not significant, a relationship between EGFL7 expression and response rates is suggested, with EGFL7 expression at the invasive front being lower in responding patients than in the non-responders (P = 0.063). Conclusion: The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA-126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics.}}, author = {{Hansen, T. F. and Christensen, R. Dp and Andersen, R. F. and Sorensen, F. B. and Johnsson, Anders and Jakobsen, A.}}, issn = {{1532-1827}}, keywords = {{angiogenesis; chemotherapy; colorectal neoplasms; epidermal growth; factor-like domain 7; microRNA; predictive biomarkers}}, language = {{eng}}, number = {{5}}, pages = {{1243--1251}}, publisher = {{Nature Publishing Group}}, series = {{British Journal of Cancer}}, title = {{MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial}}, url = {{http://dx.doi.org/10.1038/bjc.2013.448}}, doi = {{10.1038/bjc.2013.448}}, volume = {{109}}, year = {{2013}}, }